Navigation Links
Elbit Imaging Ltd. Announces Standard & Poor's Maalot Changes Rating of Company's Notes
Date:9/12/2012

TEL AVIV, Israel, September 12, 2012 /PRNewswire/ --

Elbit Imaging Ltd. ("EI" or the "Company") (TASE, NASDAQ: EMITF) announced today, that Standard & Poor's Maalot, has decided to change the rating of all of the Company's Series A through Series G Notes and Series 1 Notes, which are traded on the Tel Aviv Stock Exchange, from an "ilBBB+/Negative" credit rating, to an "ilBBB/Negative" credit rating.

 

About Elbit Imaging Ltd.

Elbit Imaging Ltd. operates in the following principal fields of business: (i) Commercial and Entertainment Centers - Initiation, construction and sale of shopping and entertainment centers and other mixed-use real property projects, predominantly in the retail sector, located in Central and Eastern Europe and in India, primarily through its subsidiary Plaza Centers N.V. In certain circumstances and depending on market conditions, we operate and manage commercial and entertainment centers prior to their sale; (ii) U.S. Real Property - Investment in commercial real property in the United States; (iii) Hotels - Hotel operation and management; (iv) Medical Industries - (a) research and development, production and marketing of magnetic resonance imaging guided focused ultrasound treatment equipment and (b) development of stem cell population expansion technologies and stem cell therapy products for transplantation and regenerative medicine; (v) Residential Projects - Initiation, construction and sale of residential projects and other mixed-use real property projects, predominately residential, located primarily in India; (vi) Fashion Apparel - Distribution and marketing of fashion apparel and accessories in Israel; and (vii) Other Activities - (a) venture capital investments and (b) potential investments in hospitals and farm and dairy plants in India. We have presently decided to suspend our investment activities in hospitals and farm and dairy plants in India until we are satisfied that the economy has recovered sufficiently to resume such activities.

Any forward-looking statements in our releases include statements regarding the intent, belief or current expectations of Elbit Imaging Ltd. and our management about our business, financial condition, results of operations, and its relationship with its employees and the condition of our properties. Words such as "believe," "expect," "intend," "estimate" and similar expressions are intended to identify forward-looking statements but are not the exclusive means of identifying such statements. Actual results may differ materially from those projected, expressed or implied in the forward-looking statements as a result of various factors including, without limitation, the factors set forth in our filings with the Securities and Exchange Commission including, without limitation, Item 3.D of our annual report on Form 20-F for the fiscal year ended December 31, 2011, under the caption "Risk Factors." Any forward-looking statements contained in our releases speak only as of the date of such release, and we caution existing and prospective investors not to place undue reliance on such statements. Such forward-looking statements do not purport to be predictions of future events or circumstances, and therefore, there can be no assurance that any forward-looking statement contained our releases will prove to be accurate. We undertake no obligation to update or revise any forward-looking statements.


For Further Information:

Company Contact: Shimon Yitzhaki Chairman of the Board of Directors Tel: +972-3-608-6048 shimony@elbitimaging.com Mor Dagan Investor Relations Tel: +972-3-516-7620 mor@km-ir.co.il


'/>"/>
SOURCE Elbit Imaging Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Elbit Imaging Ltd. Announces Second Quarter Results for 2012
2. Novelos Therapeutics And Academic Collaborators Present Three Posters At 2012 World Molecular Imaging Congress
3. Frost & Sullivan Acknowledges the Value Dell Healthcare and Life Sciences Brings to the Enterprise Imaging Informatics Marketplace
4. ImaginAb and MacroGenics Collaborate to Develop In Vivo Imaging Agents for Autoimmune Diseases, Cancer
5. GE Healthcare Imaging Equipment now available in Attainias Equipment Planning System
6. VISTA Imaging Services, Inc. Ranks No. 881 on the 2012 Inc. 500
7. 5000 with Three-Year Sales Growth of 376%
8. Caliber Imaging & Diagnostics Releases New Products for Noninvasive, Rapid Imaging of Living Cells
9. Positrons Attrius PET Scanner Now Utilized In Alzheimers Imaging With Amyvid Agent
10. Lucid, Inc. Reflects New Vision with Name Change to Caliber Imaging & Diagnostics, Inc.
11. American Radiology Services to offer New Alzheimers Disease Imaging Technique
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), a ... significant unmet medical needs, today announced that it ... product development program, based on its proprietary self-delivering ... Dermatology (SID) 76 th Annual Meeting.  The ... sciences relevant to skin health and disease through ...
(Date:4/20/2017)... , April 20, 2017  AbbVie (NYSE: ... 99 percent (n=145/146) of chronic hepatitis C virus ... 5 or 6 and compensated cirrhosis (Child-Pugh A) ... (SVR 12 ) with its investigational, pan-genotypic regimen ... rates were seen following 12 weeks of G/P ...
(Date:4/20/2017)... Research and Markets has announced the ... Market Analysis By Service (Manufacturing, Research), By Country, (Brazil, Mexico, ... report to their offering. ... The Latin American pharmaceutical contract manufacturing services market ... Low drug registration cost in Latin American countries and ...
Breaking Medicine Technology:
(Date:4/24/2017)... , ... April 24, 2017 , ... ... of unique liquid food supplements, announced its popular products are now available for ... , ALP Nutrition® prioritizes the use of premium natural ingredients in making all ...
(Date:4/24/2017)... ... April 24, 2017 , ... Salus ... announces the company’s VideoMedicine mobile platform has launched Quick Care, a new service ... day, Quick Care provides patients with the option to request and begin a ...
(Date:4/24/2017)... ... April 24, 2017 , ... In 2017, up to ... approximately 25,000 of them will be malignant.(1) As research into precision medicine continues, ... healthcare model in the diagnosis and treatment of brain tumors. Healthcare facilities that ...
(Date:4/24/2017)... ... April 24, 2017 , ... Pitavastatin, ... HIV because it is not known to have significant interactions with antiretroviral therapy ... both lower cholesterol levels and dampen inflammation in the bloodstream. , While lowering ...
(Date:4/24/2017)... ... April 24, 2017 , ... Labs often perform the ... for lab operators and management to assess these processes with a critical eye—particularly ... unnecessary actions. , Created with the help of both internal and external ...
Breaking Medicine News(10 mins):